Economy - published on 03 June 2020
Source: European Commission Spokesperson’s Service
The European Commission has waived, under the EU Merger Regulation, the commitments made by Takeda to obtain clearance of its acquisition of Shire. The Commission approved the acquisition of Shire
by Takeda on 20 November
2018, subject to the divestment of a biologic drug under development by Shire to treat inflammatory bowel diseases (“IBD”), namely SHP 647. Upon receipt of the request by Takeda to waive the
commitments, the Commission has initiated a market investigation to determine whether a waiver is justified in light of the changed market conditions and developments. The Commission’s
investigation revealed that several permanent, significant and unforeseeable developments took place during the divestiture process, affecting both the evolution of the competitive landscape in IBD
treatments and the development of Shire’s pipeline drug. The Commission concluded that the combination of these developments amounted to exceptional circumstances so that the divestment of SHP 647
was no longer necessary to render Takeda’s acquisition of Shire compatible with the internal market. As a result, the Commission has decided to waive the commitments submitted by Takeda in
November 2018, in their entirety.
Economy 2 giorni fa
The Chamber of Commerce for Gender Equality
Economy 5 giorni fa
Innovation to attract young people to agriculture
